Baclofen

Baclofen

• Baclofen is a centrally acting antispastic agent that exerts its effects on GABA_B receptors located on both presynaptic and postsynaptic neurons in the brain and spinal cord.^1.2 The net effect is reducing excitatory signaling within spinal pathways and lowering muscle hyper-reactivity.
• Baclofen has good oral bioavailability, a short elimination half-life, and is primarily eliminated as an unchanged drug by the kidneys. Intrathecal administration is utilized when high concentrations within the spinal cord are required.

Mechanism of Action

• Baclofen is a structural analogue of γ‑aminobutyric acid (GABA) and acts as a GABA_B receptor agonist on pre‑ and postsynaptic neurons in the CNS.
• Presynaptically, baclofen reduces calcium influx and decreases the release of excitatory neurotransmitters such as glutamate. Postsynaptically, it increases potassium conductance and hyperpolarizes neurons, suppressing mono‑ and polysynaptic spinal reflexes and relieving spasticity (Figure 1).

Pharmacodynamic Effects

• The principal effect of baclofen is the reduction in frequency and severity of muscle spasms, clonus, and associated pain in conditions such as MS and SCI.
• Baclofen produces CNS depression, commonly manifesting as sedation, somnolence, and ataxia. It also has antinociceptive, muscle‑relaxant, and modest anti‑inflammatory/neuroprotective effects through microglial and astrocyte modulation.

Pharmacokinetics

• Absorption: Oral bioavailability is estimated 70–85% with peak plasma concentrations occurring within 2–3 hours. Absorption is dose‑dependent.
• Distribution: Volume of distribution ~0.7–1 L/kg with relatively low plasma protein binding of 30%. Due to hydrophilic properties, CNS penetration is limited after oral ingestion. Intrathecal delivery allows therapeutic cerebrospinal fluid (CSF) levels with plasma levels that are about 100‑fold lower than the oral dosing.

Metabolism and Elimination

• Baclofen undergoes little hepatic metabolism; most of the dose is excreted unchanged in the urine.
• Elimination half‑life is typically 2–4 hours, although some data reported up to ~6–7 hours using combined serum and urine methods. Given the relatively short half- life, multiple daily oral doses are required.
• Because approximately 70–80% of baclofen is eliminated via renal excretion, dose reduction is essential in renal impairment to avoid drug accumulation and toxicity (Table 1). It is generally avoided in patients requiring dialysis. Hepatic impairment does not require dose modification due to minimal hepatic metabolism.³

Oral versus Intrathecal Baclofen

• Baclofen may be administered orally, intravenously, or intrathecally. Intrathecal baclofen achieves high CSF concentrations with lower systemic exposure and is considered superior in patients who do not respond to oral therapy.

Differences in Clinical Effects

• At long-term follow-up, intrathecal baclofen has been shown to reduce both the frequency and severity of muscle spasms more effectively than oral baclofen, with greater dose stability over time.
• Direct delivery to the spinal cord allows more effective reduction of muscle tone, spasms, and associated pain, which may translate into improvements in posture, functional transfers, and sleep quality in patients with severe spasticity.

Adverse Effect Profile

• Oral therapy is commonly associated with drowsiness, confusion, dizziness, nausea, and generalized weakness, which limit dose escalation.
• Intrathecal therapy uses much smaller doses, so systemic CNS side effects (sedation, confusion) are generally reduced. However, pump/catheter related complications, over‑ or under‑infusion, and life‑threatening withdrawal or overdose can occur and require urgent recognition and management

Baclofen Toxicity

• Toxicity reflects excessive exposure to baclofen, often associated with reduced clearance, dosing errors, or intrathecal device malfunction. Clinical manifestations often resemble other CNS depressant overdoses, which can delay diagnosis. Intrathecal therapy has a higher risk of causing severe adverse effects.^3,4
• Typical symptoms include sedation, confusion, hypotonia, dizziness, nausea, and respiratory depression. Severe toxicity may produce seizures, hypotension, autonomic instability, neuropsychiatric changes, and cardiovascular abnormalities.

Treatment of Baclofen Toxicity

• Because no dedicated reversal agent exists for baclofen overdose, treatment relies on early recognition, cessation of further exposure, and supportive management.^2-4

Management includes:

• Airway protection and mechanical ventilation for respiratory depression^2,3
• Hemodynamic support with atropine for bradycardia⁴
• Prompt removal of the drug from the gastrointestinal tract through emesis in conscious patients or gastric lavage (oral baclofen overdose)^2-4
• Benzodiazepines as first-line treatment for seizures³
• Hemodialysis for patients with renal failure since baclofen is dialyzable^2-4
• Empty intrathecal pump reservoir if applicable⁴
• Consider removal of 30–40 mL CSF via lumbar puncture if not contraindicated⁴
• Clinical monitoring should continue until symptoms resolve and drug levels return to a safe range.

Baclofen Withdrawal

• Baclofen withdrawal is a potentially life-threatening condition, most commonly associated with interruption of intrathecal baclofen delivery.³ Causes include catheter obstruction, pump malfunction, reservoir depletion, or battery failure. Withdrawal may be mistaken for infection, autonomic dysfunction, or neuroleptic malignant syndrome.³
• Sudden loss of baclofen exposure can lead to rapidly worsening withdrawal symptoms, beginning with marked rebound spasticity and often progressing to agitation, sensory disturbances, delirium, autonomic instability, hyperthermia, rhabdomyolysis, and seizures. If untreated, withdrawal can progress to multiorgan failure, respiratory collapse, and death.

Management

• The primary therapeutic priority is to reestablish baclofen delivery as quickly as possible, preferably via the intrathecal route.³ Early recognition and rapid correction of delivery failure are essential to prevent morbidity and mortality.

Management includes:

• High-dose oral baclofen if prompt intrathecal administration is not possible
• Benzodiazepines, cyproheptadine, dexmedetomidine, dantrolene, or propofol to control agitation or autonomic instability³
• Supportive measures include hydration, temperature control, and monitoring for rhabdomyolysis and renal injury
• Intensive care unit-level monitoring and care for acute withdrawal management